CClinicalTrials.gg
Not yet recruitingNCT06832813Updated Apr 3, 2025

Long Term Efficacy and Safety of TMS Targeting Cerebellum to Treat DRE

An interventional study of cTBS in Drug-resistant Epilepsy and Transcranial Magnetic Stimulation, sponsored by Xijing Hospital. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-04-03.

Sponsored by Xijing Hospital · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This study aims to observe the long term efficacy and safety of cerebellar continuous θ burst stimulation (cTBS) for drug-resistant Epilepsy during enhanced and maintenance phase,in order to provide a new treatment for long-term control of drug-resistant epilepsy and improve the quality of life of those patients. A total of 100 patients with DRE will undergo cTBS treatment by precise navigation to bilateral cerebellar dentate nuclei. The frequency and clinical feature of seizures, scalp EEG,clinical score, MOCA,MMSE,and QOLIE-31 were ssessed at baseline, after 2 weeks of enhanced phase,8 weeks of consolidate phase, and 8 weeks of maintenance phase.

02

Conditions studied

  • Drug-resistant Epilepsy
  • Transcranial Magnetic Stimulation
03

In context

Epilepsy

1,805 studies on the registry are indexed under Epilepsy; 417 are open to participants now.

This study's planned enrollment of 100 is above the median of 50 across 1,206 interventional studies indexed under Epilepsy.

Browse Epilepsy studies →

Lead sponsor

Xijing Hospital is the lead sponsor of 465 studies on the registry; 157 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Age 18-65 years old,
  2. Participants who are diagnosed as drug- resistant epilepsy,
  3. Participants who has a history of DRE ≥2 years before enrollment,
  4. Participants who has a seizure frequency of ≥2 seizures every month within 3 months before enrollment,
  5. Participants and their families are aware of this study and sign informed consent.

Exclusion criteria

Exclusion Criteria:

  1. Participants who are in status epilepticus,
  2. Participants who are complicated with serious infection, cerebrovascular disease, malignant tumor and other nervous system diseases, with serious dysfunction of heart, liver, kidney and other organs, and with psychiatric disorders,
  3. Participants plan invasive therapy, such as operation,
  4. Participants who are in pregnancy or lactating,
  5. Patients cannot tolerate repeated transcranial magnetic stimulation, or have contraindications of repeated transcranial magnetic stimulation.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Participant Group

    Continuous θ-burst stimulation (cTBS) is characterized by plexus stimulation. The stimulation intensity was 80% resting motor threshold (RMT) at 50Hz of intra plexus pulse while the frequency of inter plexus pulse is 5Hz, the duration was 40s, and the number of stimulation pulses was 600. Two groups of stimulation were repeated in each cerebellar dentate nucleus with an interval of 5 min in each group.

    Device: cTBS

Interventions

  • DevicecTBS

    Continuous θ-burst stimulation (cTBS) is characterized by plexus stimulation. The stimulation intensity was 80% resting motor threshold (RMT) at 50Hz of intra plexus pulse while the frequency of inter plexus pulse is 5Hz, the duration was 40s, and the number of stimulation pulses was 600. Two groups of stimulation were repeated in each cerebellar dentate nucleus with an interval of 5 min in each group. 1. Enhanced phase:participants received cTBS treatment for a total of 5 times a week for 2 weeks; 2. Consolidation phase:participants received cTBS treatment for a total of twice a week (at least 24 hours apart) for 8 weeks; 3. Maintenance phase:participants received cTBS treatment for a total of once a week for 8 weeks.

06

What researchers measure

Primary outcomes

  1. seizure reduction rate

    A 28-day baseline for seizure frequency will be recorded by the patients themselves or their guardian before therapy and then compare to the frequency after enhanced phase /consolidation/maintenance treatment / 8 weeks after the end of all treatment

    Time frame: Enhanced phase: 2 weeks;Consolidation phase:8 weeks; Maintenance phase:8 weeks; Follow up phase:8 weeks

  2. responder rate

    proportion of people with a 50% or greater reduction in seizure frequency following enhanced phase /consolidation/maintenance treatment / 8 weeks after the end of all treatment

    Time frame: Enhanced phase: 2 weeks;Consolidation phase:8 weeks; Maintenance phase:8 weeks; Follow up phase:8 weeks

Secondary outcomes

  1. QOLIE-31 scale scores

    Quality of Life in Epilepsy-31. Scores range from 0 to 100, with higher scores indicating better quality of life.

    Time frame: Enhanced phase: 2 weeks;Consolidation phase:8 weeks; Maintenance phase:8 weeks; Follow up phase:8 weeks

  2. scalp electroencephalogram

    Routine scalp electroencephalogram at 40 min

    Time frame: Enhanced phase: 2 weeks;Consolidation phase:8 weeks; Maintenance phase:8 weeks; Follow up phase:8 weeks

  3. MRI

    Diffusion tensor imaging,Functional MRI

    Time frame: Enhanced phase: 2 weeks;Consolidation phase:8 weeks; Maintenance phase:8 weeks; Follow up phase:8 weeks

  4. MoCA

    Montreal Cognitive Assessment. A max score is 30 points, and a score ≥ 26 is considered normal.

    Time frame: Enhanced phase: 2 weeks;Consolidation phase:8 weeks; Maintenance phase:8 weeks; Follow up phase:8 weeks

  5. MMSE

    Mini-Mental State Examination. The normal values are defined as: illiterates \>17, primary school \>20, junior high school or above \>24.

    Time frame: Enhanced phase: 2 weeks;Consolidation phase:8 weeks; Maintenance phase:8 weeks; Follow up phase:8 weeks

07

Study locations

1 site
  • Xijing Hospital
    Xi'an, Shaanxi 710032, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06832813
Lead sponsor
Xijing Hospital
Responsible party
Sponsor
First posted
Feb 18, 2025
Start date
Mar 28, 2025 (estimated)
Primary completion
Mar 27, 2027 (estimated)
Completion
Mar 27, 2027 (estimated)
Last update
Apr 3, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion